𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Vaccination with p53-peptide–pulsed dendritic cells, of patients with advanced breast cancer: report from a phase I study

✍ Scribed by IngeMarie Svane; AndersE. Pedersen; HansE. Johnsen; Dorte Nielsen; Claus Kamby; Eva Gaarsdal; Kirsten Nikolajsen; Søren Buus; MogensH. Claesson

Publisher
Springer-Verlag
Year
2004
Tongue
English
Weight
443 KB
Volume
53
Category
Article
ISSN
0340-7004

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Phase I study in melanoma patients of a
Phase I study in melanoma patients of a vaccine with peptide-pulsed dendritic cells generated in vitro from CD34+ hematopoietic progenitor cells
✍ Andreas Mackensen; Birgit Herbst; Ji-Li Chen; Gabriele Köhler; Christoph Noppen; 📂 Article 📅 2000 🏛 John Wiley and Sons 🌐 French ⚖ 268 KB 👁 2 views

Dendritic cells (DCs) are professional antigen-presenting cells (APCs) that can be used for vaccination purposes, to induce a specific T-cell response in vivo against melanomaassociated antigens. We have shown that the sequential use of early-acting hematopoietic growth factors, stem cell factor, IL

Ex vivo ras peptide vaccination in patie
Ex vivo ras peptide vaccination in patients with advanced pancreatic cancer: Results of a phase I/II study
✍ Marianne K. Gjertsen; Arne Bakka; Jarle Breivik; Ingvil Saeterdal; Tobias Gedde- 📂 Article 📅 1996 🏛 John Wiley and Sons 🌐 French ⚖ 434 KB 👁 2 views

In a pilot phase 1/11 study we have tested synthetic ras peptides used as a cancer vaccine in 5 patients with advanced pancreatic carcinoma. The treatment principle used was based on loading professional antigen-presenting cells (APCs) from peripheral blood with a synthetic ras peptide corresponding